SANDOZ DARUNAVIR TABLET Kanada - angličtina - Health Canada

sandoz darunavir tablet

sandoz canada incorporated - darunavir - tablet - 800mg - darunavir 800mg - hiv protease inhibitors

SYMTUZA- darunavir, cobicistat, emtricitabine, and tenofovir alafenamide tablet, film coated Spojené štáty - angličtina - NLM (National Library of Medicine)

symtuza- darunavir, cobicistat, emtricitabine, and tenofovir alafenamide tablet, film coated

janssen products lp - darunavir (unii: yo603y8113) (darunavir - unii:yo603y8113), cobicistat (unii: lw2e03m5pg) (cobicistat - unii:lw2e03m5pg), emtricitabine (unii: g70b4etf4s) (emtricitabine - unii:g70b4etf4s), tenofovir alafenamide (unii: el9943ag5j) (tenofovir anhydrous - unii:w4hfe001u5) - symtuza is indicated as a complete regimen for the treatment of human immunodeficiency virus type 1 (hiv-1) infection in adults and pediatric patients weighing at least 40 kg: - who have no prior antiretroviral treatment history or - who are virologically suppressed (hiv-1 rna less than 50 copies per ml) on a stable antiretroviral regimen for at least 6 months and have no known substitutions associated with resistance to darunavir or tenofovir. darunavir and cobicistat are both inhibitors of the cytochrome p450 3a (cyp3a) isoform. symtuza should not be co-administered with medicinal products that are highly dependent on cyp3a for clearance and for which increased plasma concentrations are associated with serious and/or life-threatening events (narrow therapeutic index). darunavir and cobicistat are both substrates of the cytochrome p450 3a (cyp3a) isoform. co-administration of symtuza with cyp3a inducers is expected to lower plasma concentrations of darunavir and cobicistat which may lead to loss of efficacy

Darunavir Sandoz 150 mg film-coat. tabl. Belgicko - angličtina - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

darunavir sandoz 150 mg film-coat. tabl.

sandoz sa-nv - darunavir 150 mg - film-coated tablet - 150 mg - darunavir 150 mg - darunavir